One Wealth Capital Management LLC Buys New Position in IDEXX Laboratories, Inc. $IDXX

One Wealth Capital Management LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 1,339 shares of the company’s stock, valued at approximately $699,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Aurora Investment Managers LLC. bought a new position in IDEXX Laboratories in the second quarter valued at $2,442,000. National Pension Service lifted its stake in IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after purchasing an additional 6,885 shares during the last quarter. NewEdge Advisors LLC lifted its stake in IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after purchasing an additional 5,761 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock worth $11,988,000 after purchasing an additional 1,074 shares in the last quarter. Finally, NEOS Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 12.5% in the 2nd quarter. NEOS Investment Management LLC now owns 60,354 shares of the company’s stock worth $31,773,000 after purchasing an additional 6,721 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $560.38 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock’s 50 day simple moving average is $532.69 and its 200 day simple moving average is $551.64. The firm has a market cap of $44.15 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.99 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on IDXX shares. Barclays reduced their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. KeyCorp assumed coverage on IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating for the company. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. The Goldman Sachs Group initiated coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. Finally, UBS Group lifted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $744.09.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.